Skip Navigation and Go To Content
News from The University of Texas Health Science Center at Houston

Stories from The University of Texas Health Science Center at Houston (UTHealth Houston)

Navigation and Search

Research






UTHealth Houston researchers begin five-year study into effectiveness and safety of whole blood transfusion

Bags of donated blood before a transfusion, sitting on a table during a surgery

October 24, 2022

Funded by the National Heart Lung, and Blood Institute (NHLBI), the “Trauma Resuscitation with Group O Whole Blood Or Products” (TROOP) trial will enroll 1,200 patients at 12 trauma centers across the United States, to compare whole blood transfusions to blood component therapy, the current standard in trauma transfusions. Enrollment for TROOP will begin in spring 2023.

 


Yammine receives $2.25 million NIDA grant to study smoking cessation

Luba Yammine, PhD, associate professor in the Faillace Department of Psychiatry and Behavioral Sciences at McGovern Medical School. (Photo by UTHealth Houston)

August 22, 2022

A four-year, $2.25 million grant to identify a novel approach for facilitating smoking abstinence and limiting post-smoking cessation weight gain has been awarded to UTHealth Houston researcher Luba Yammine, PhD, by the National Institute on Drug Abuse (NIDA).



Fernandez receives ASPPH Research Excellence Award

Maria E. Fernandez. PhD

December 20, 2021

 Maria E. Fernandez, PhD, the Lorne Bain Distinguished Professor in Public Health and Medicine, and professor of health promotion and behavioral science at UTHealth School of Public Health is the recipient of the 2022 Association of Schools and Programs of Public Health’s (ASPPH) Research Excellence Award. This distinguished award recognizes faculty who have devoted their careers to investigating public health issues. 


Preclinical research reveals that new IgM antibodies administered intranasally to fight COVID-19 more potent than commonly used ones

Photo of Zhiqiang An, PhD, who was one of the lead authors  of a study that revealed engineered IgM antibodies were more potent than standard ones against COVID-19. (Photo by UTHealth)

June 3, 2021

A nasal therapy, built upon on the application of a new engineered IgM antibody therapy for COVID-19, was more effective than commonly used IgG antibodies at neutralizing the COVID-19 virus in animal models, according to research recently published by The University of Texas Health Science Center at Houston (UTHealth), The University of Texas Medical Branch at Galveston (UTMB Health), the University of Houston, and IGM Biosciences, Inc. 



Page 19 of 20

More headlines »

Search UTHealth Houston News

Use the form below to perform a new search.

Give to UTHealth Houston